乳腺癌相关治疗中细胞周期蛋白依赖性激酶4和6抑制剂机制相关的研究进展
Research Progress in the Related Mechanisms of Cyclin-Dependent Kinase 4 and 6 Inhibitors in the Treatment of Breast Cancer
DOI: 10.12677/ACM.2023.13112580, PDF,   
作者: 乌尔肯·别克拉米斯：新疆医科大学第三临床学院，新疆 乌鲁木齐；甫拉提·吾瓦力汗*：新疆维吾尔自治区肿瘤医院乳腺外科二病区，新疆 乌鲁木齐
关键词: 乳腺癌；CDK4/6抑制剂；耐药机制；Breast Cancer； CDK4/6 Inhibitor； Resistance Mechanism
摘要: 乳腺恶性肿瘤是世界上女性当中很常见的一类癌症，同时它的发病率和致死率每年都在上升。激素受体阳性(Hormone receptor positive type, HR+)乳腺癌及人表皮生长因子受体2阴性(human epi-dermal growth factor receptor 2-negative, HER2−)乳腺癌是最为常见的类型，内分泌治疗是它的主要治疗手段，同时药物出现耐药，影响疗效的情况也常发生。细胞周期蛋白依赖性激酶4和6 (cy-clin-dependent kinase 4 and 6, CDK4/6)抑制剂是一种细胞靶向药物，它与内分泌治疗药物的联合应用为HR+/HER2−乳腺癌患者提供了新的治疗方案，并且具有疗效好、副作用小等优点。尽管CDK4/6抑制剂在乳腺恶性肿瘤的治疗方面得到了很好的应用，但是它的分子生物学以及相关药理学方面的研究依然不断地在进行。现就以CDK4/6抑制剂相关作用机制、耐药机制方面予以综述。
Abstract: Breast malignancy is a very common type of cancer among women in the world, and its incidence and mortality are increasing every year. Hormone receptor positive type (HR+), Human epidermal growth factor receptor 2-negative (HER2−) breast cancer are the most common type, endocrine therapy is its main treatment, while drug resistance, the situation of affecting the efficacy also often occur. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are cell-targeted agents, and their combination with endocrine therapy agents offers a new treatment option for HR+/HER2− breast cancer patients. It has the advantages of good curative effect and little side effect. Although CDK4/6 inhibitors have been well used in the treatment of breast malignant tumors, its molecular biology and related pharmacological studies are still ongoing. This article reviews the mechanism of action and drug resistance of CDK4/6 inhibitors.
文章引用：乌尔肯·别克拉米斯, 甫拉提·吾瓦力汗. 乳腺癌相关治疗中细胞周期蛋白依赖性激酶4和6抑制剂机制相关的研究进展[J]. 临床医学进展, 2023, 13(11): 18374-18381. https://doi.org/10.12677/ACM.2023.13112580

参考文献

[1] Siegel, R.L., et al. (2023) Cancer Statistics, 2023. CA: A Cancer Journal for Clinicians, 73, 17-48. [Google Scholar] [CrossRef] [PubMed]
[2] Lüönd, F., Tiede, S. and Christofori, G. (2021) Breast Cancer as an Exam-ple of Tumour Heterogeneity and Tumour Cell Plasticity during Malignant Progression. British Journal of Cancer, 125, 164-175. [Google Scholar] [CrossRef] [PubMed]
[3] Lim, E., Metzger-Filho, O. and Winer, E.P. (2012) The Natural History of Hormone Receptor-Positive Breast Cancer. Oncology, 26, 688-694, 696.
[4] Huang, J., et al. (2022) CDK4/6 Inhibitor Resistance Mechanisms and Treatment Strategies (Review). International Journal of Molecular Medi-cine, 50, Article No. 128. [Google Scholar] [CrossRef] [PubMed]
[5] Huang, T., et al. (2023) The Effect and Safety of CDK4/6 Inhibitors Combined Endocrine Therapy on HR+, HER2− Breast Cancer: A Meta-Analysis of Ran-domized Controlled Trials. Endokrynologia Polska, 74, 89-105. [Google Scholar] [CrossRef] 
[6] Stanciu, I.M., et al. (2023) Mechanisms of Resistance to CDK4/6 In-hibitors and Predictive Biomarkers of Response in HR+/HER2− Metastatic Breast Cancer—A Review of the Literature. Diagnostics, 13, Article 987. [Google Scholar] [CrossRef] [PubMed]
[7] Cetin, B., Wabl, C.A. and Gumusay, O. (2022) CDK4/6 Inhibi-tors: Mechanisms of Resistance and Potential Biomarkers of Responsiveness in Breast Cancer. Future Oncology, 18, 1143-1157. [Google Scholar] [CrossRef] [PubMed]
[8] Nabieva, N. and Fasching, P.A. (2023) CDK4/6 Inhibi-tors-Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer. Can-cers, 15, Article 1763. [Google Scholar] [CrossRef] [PubMed]
[9] Asghar, U., et al. (2015) The History and Future of Targeting Cy-clin-Dependent Kinases in Cancer Therapy. Nature Reviews Drug Discovery, 14, 130-146. [Google Scholar] [CrossRef] [PubMed]
[10] Chaikovsky, A.C. and Sage, J. (2018) Beyond the Cell Cycle: Enhancing the Immune Surveillance of Tumors via CDK4/6 Inhibition. Molecular Cancer Research, 16, 1454-1457. [Google Scholar] [CrossRef] 
[11] Deng, J., et al. (2018) CDK4/6 Inhibition Augments Anti-tumor Immunity by Enhancing T-Cell Activation. Cancer Discovery, 8, 216-233. [Google Scholar] [CrossRef] 
[12] De Simone, M., et al. (2016) Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells. Immunity, 45, 1135-1147. [Google Scholar] [CrossRef] [PubMed]
[13] Fassl, A., Geng, Y. and Sicinski, P. (2022) CDK4 and CDK6 Kinases: From Basic Science to Cancer Therapy. Science, 375, eabc1495. [Google Scholar] [CrossRef] [PubMed]
[14] Smirnov, A., et al. (2016) FOXM1 Regulates Proliferation, Senes-cence and Oxidative Stress in Keratinocytes and Cancer Cells. Aging, 8, 1384-1397. [Google Scholar] [CrossRef] [PubMed]
[15] Vijayaraghavan, S., et al. (2017) CDK4/6 and Autophagy Inhibitors Synergistically Induce Senescence in Rb Positive Cytoplasmic Cyclin E Negative Cancers. Nature Communications, 8, Article No. 15916. [Google Scholar] [CrossRef] [PubMed]
[16] Wu, Q. and Sharma, D. (2023) Autophagy and Breast Cancer: Con-nected in Growth, Progression, and Therapy. Cells, 12, Article 1156. [Google Scholar] [CrossRef] [PubMed]
[17] Goel, S., et al. (2017) CDK4/6 Inhibition Triggers Anti-Tumour Im-munity. Nature, 548, 471-475. [Google Scholar] [CrossRef] [PubMed]
[18] Wang, H., et al. (2017) The Metabolic Function of Cyclin D3-CDK6 Ki-nase in Cancer Cell Survival. Nature, 546, 426-430. [Google Scholar] [CrossRef] [PubMed]
[19] Xi, J. and Ma, C.X. (2020) Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do after Disease Progression on a CDK4/6 Inhibitor? Current Oncology Reports, 22, Article No. 57. [Google Scholar] [CrossRef] [PubMed]
[20] Scheidemann, E.R. and Shajahan-Haq, A.N. (2021) Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer. International Journal of Molecular Sciences, 22, Ar-ticle 12292. [Google Scholar] [CrossRef] [PubMed]
[21] Dean, J.L., et al. (2012) Therapeutic Response to CDK4/6 Inhibition in Breast Cancer Defined by ex Vivo Analyses of Human Tumors. Cell Cycle, 11, 2756-2761. [Google Scholar] [CrossRef] [PubMed]
[22] Malorni, L., et al. (2016) A Gene Expression Signature of Retinoblastoma Loss-of-Function Is a Predictive Biomarker of Resistance to Palbociclib in Breast Cancer Cell Lines and Is Prognostic in Patients with ER Positive Early Breast Cancer. Oncotarget, 7, 68012-68022. [Google Scholar] [CrossRef] [PubMed]
[23] Gomatou, G., et al. (2021) Mechanisms of Resistance to Cy-clin-Dependent Kinase 4/6 Inhibitors. Molecular Biology Reports, 48, 915-925. [Google Scholar] [CrossRef] [PubMed]
[24] Sobhani, N., et al. (2019) Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer. Cells, 8, 321. [Google Scholar] [CrossRef] 
[25] Casimiro, M.C., et al. (2012) ChIP Sequencing of Cyclin D1 Reveals a Transcriptional Role in Chromosomal Instability in Mice. Journal of Clinical Investigation, 122, 833-843. [Google Scholar] [CrossRef] 
[26] Abdelmalak, M., et al. (2022) The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance. Cancers, 14, Article 5388. [Google Scholar] [CrossRef] [PubMed]
[27] Franco, J., Witkiewicz, A.K. and Knudsen, E.S. (2014) CDK4/6 In-hibitors Have Potent Activity in Combination with Pathway Selective Therapeutic Agents in Models of Pancreatic Can-cer. Oncotarget, 5, 6512-6525. [Google Scholar] [CrossRef] [PubMed]
[28] Turner, N., et al. (2010) FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer. Cancer Research, 70, 2085-2094. [Google Scholar] [CrossRef] 
[29] André, F., et al. (2021) Alpelisib plus Fulvestrant for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Final Overall Survival Results from SOLAR-1. Annals of Oncology, 32, 208-217. [Google Scholar] [CrossRef] [PubMed]
[30] Herrera-Abreu, M.T., et al. (2016) Early Adaptation and Ac-quired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. Cancer Research, 76, 2301-2313. [Google Scholar] [CrossRef] 
[31] Li, Z., et al. (2018) Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. Cancer Cell, 34, 893-905.e8. [Google Scholar] [CrossRef] [PubMed]
[32] Formisano, L., et al. (2019) Aberrant FGFR Signaling Mediates Resistance to CDK4/6 Inhibitors in ER+ Breast Cancer. Nature Communications, 10, Article No. 1373. [Google Scholar] [CrossRef] [PubMed]
[33] Gong, X., et al. (2017) Genomic Aberrations that Activate D-Type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib. Cancer Cell, 32, 761-776.e6. [Google Scholar] [CrossRef] [PubMed]
[34] McCartney, A., et al. (2019) Prognostic Role of Serum Thymidine Kinase 1 Activity in Patients with Hormone Receptor-Positive Metastatic Breast Cancer: Analysis of the Randomised Phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT). European Journal of Cancer, 114, 55-66. [Google Scholar] [CrossRef] [PubMed]
[35] Cocco, S., et al. (2020) Targeting Autophagy in Breast Cancer. In-ternational Journal of Molecular Sciences, 21, Article 7836. [Google Scholar] [CrossRef] [PubMed]

为你推荐